| PERIOD ENDING | 31-Mar-04 | | Total Revenue | 7,147,585 | | Cost of Revenue | 2,239,037 | | | Gross Profit | 4,908,548 | | | Operating Expenses | | Research Development | 716,474 | | Selling General and Administrative | 969,792 | | Non Recurring |
-
| | Others | 80,738 | | | | Total Operating Expenses |
-
| | | | Operating Income or Loss | 3,141,544 | | | Income from Continuing Operations | | Total Other Income/Expenses Net | 573 | | Earnings Before Interest And Taxes | 3,142,117 | | Interest Expense |
-
| | Income Before Tax | 3,142,117 | | Income Tax Expense |
-
| | Minority Interest |
-
| | | | Net Income From Continuing Ops | 3,142,117 | | | Non-recurring Events | | Discontinued Operations |
-
| | Extraordinary Items |
-
| | Effect Of Accounting Changes |
-
| | Other Items |
-
| | | | Net Income | 3,142,117 | | Preferred Stock And Other Adjustments |
-
| | | Net Income Applicable To Common Shares | $3,142,117 |
|
0.51% Nasdaq 
0.36 (3.38%) 
Income Statement
